Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)

被引：0
|
作者：
Mazzeo, R. [1 ]
Bortot, L. [1 ]
Michelotti, A. [1 ]
Buriolla, S. [1 ]
Palmero, L. [1 ]
Franzoni, A. [2 ]
Bertoli, E. [1 ]
Targato, G. [1 ]
Allegri, L. [2 ]
Da Ros, L. [3 ]
Alberti, M. [1 ]
Di Nardo, P. [3 ]
Bonotto, M. [4 ]
Sodde, S. [5 ]
Belletti, B. [6 ]
Spazzapan, S. [3 ]
Baldassarre, G. [6 ]
Damante, G. [2 ]
Gerratana, L. [1 ]
Puglisi, F. [3 ]
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] Azienda Sanit Univ Friuli Cent ASUFC Udine, Inst Human Genet, Udine, Italy
[3] Ctr Riferimento Oncol CRO IRCCS, Dept Med Oncol, Aviano, Italy
[4] Azienda Sanit Univ Friuli Cent ASUFC Udine, Med Oncol, Udine, Italy
[5] Ctr Riferimento Oncol CRO IRCCS, Clin Trial Off, Aviano, Italy
[6] Ctr Riferimento Oncol CRO IRCCS, Mol Oncol Unit, Aviano, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.576
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
293P
引用
收藏
页码：S492 / S493
页数：2
相关论文
共 50 条
  • [31] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [32] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Andrahennadi, Samitha
    Sami, Amer
    Manna, Mita
    Pauls, Mehrnoosh
    Ahmed, Shahid
    CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
  • [33] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
    Gaia Griguolo
    Maria Vittoria Dieci
    Laia Paré
    Federica Miglietta
    Daniele Giulio Generali
    Antonio Frassoldati
    Luigi Cavanna
    Giancarlo Bisagni
    Federico Piacentini
    Enrico Tagliafico
    Katia Cagossi
    Guido Ficarra
    Aleix Prat
    Pierfranco Conte
    Valentina Guarneri
    npj Breast Cancer, 7
  • [34] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [35] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Liquid biopsy-based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)
    Bortot, L.
    Basile, D.
    Palmero, L.
    Dri, A.
    Cucciniello, L.
    Buriolla, S.
    Pasto, B.
    Mazzeo, R.
    Bonotto, M.
    Bolzonello, S.
    Franzoni, A.
    Allegri, L.
    Belletti, B.
    Damante, G.
    Gerratana, L.
    Minisini, A. M. M.
    Puglisi, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S656 - S657
  • [37] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Walker, Amanda J.
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shengui
    Sridhara, Rajeshwari
    Chen, Wei
    Palmby, Todd R.
    Zirkelbach, Jeanne Fourie
    Fu, Wentao
    Liu, Qi
    Tilley, Amy
    Kim, Geoffrey
    Kluetz, Paul G.
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
  • [38] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [39] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
    Griguolo, Gaia
    Dieci, Maria Vittoria
    Pare, Laia
    Miglietta, Federica
    Generali, Daniele Giulio
    Frassoldati, Antonio
    Cavanna, Luigi
    Bisagni, Giancarlo
    Piacentini, Federico
    Tagliafico, Enrico
    Cagossi, Katia
    Ficarra, Guido
    Prat, Aleix
    Conte, Pierfranco
    Guarneri, Valentina
    NPJ BREAST CANCER, 2021, 7 (01)
  • [40] Ranking of therapeutic regimens for hormone receptor-positive, HER2-negative, metastatic breast cancer (MBC) using information theoretic network meta-analysis.
    Li, Xuanyi
    Tavana, Hossein
    Bhavnani, Suresh
    Warner, Jeremy Lyle
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345